zolbetuximab
astellas
[]
#spotlight is now on the spotlight trial of zolbetuximab in advanced #gastriccancer: significant in pfs and os. interesting that median os was 18mo for this claudin 18.2 inhibitor. 18 = life #gi23
MOM. GI Onc @nyphospital @meyercancer @weillcornell. Founder @mmfightscrc @letswinpc @oceansblessings. @JAJForg @curepolg boards. cycleuptocancer on @onepeloton